A Phase 4 interventional study of VIGAMOX in Bacterial Conjunctivitis, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 1 Year to 13 Years. Per ClinicalTrials.gov, last updated 2012-11-02.
Sponsored by Alcon Research (part of Alcon) · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Conjunctivitis, Bacterial with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Conjunctivitis, Bacterial · United States.
Among the 20 studies in Conjunctivitis, Bacterial with a site in United States, this one is the 15th largest by enrollment, is one of 3 that started in 2006, is one of 3 in phase 4, and was the 3rd registered.
40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.
Browse Conjunctivitis, Bacterial studies →2 of the 20 studies in Conjunctivitis, Bacterial with a site in United States are open now. Recruiting first, the newest first:
Senju USA, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Baxis Pharmaceuticals, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Conjunctivitis, Bacterial studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 1 Year to 13 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 13 · Phase 4 3
First in 2004; this study’s year is marked. 3 started in 2006.
This study's enrollment of 137 is below the median of 261 across 36 interventional studies indexed under Conjunctivitis, Bacterial.
Median enrollment 413 across the 20 interventional studies. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Alcon has 7 studies filed under Conjunctivitis, Bacterial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Conjunctivitis, Bacterial with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.
Drug: VIGAMOX
Healthy Subjects receiving no treatment
1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation
Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI). 0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic
Time frame: Day 0 and Day 42
Susceptability Changes in Staphylococcus Aureus Distal to the Site of Instillation
Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI). 0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic
Time frame: Day 0, Day 42
Susceptability Changes in Haemophilus Influenzae Distal to the Site of Instillation
Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI). 0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic
Time frame: Day 0, Day 42
Study recruitment started in June 2006 and ran until January 29 2008. The study sites included three sites (AZ, CA and IL)
| Milestone | Infected Patients | Healthy Subjects |
|---|---|---|
| Started | 105 | 57 |
| Completed | 83 | 54 |
| Not completed | 22 | 3 |
| Withdrew: Adverse event | 7 | 2 |
| Withdrew: Lost to follow-up | 9 | 1 |
| Withdrew: Withdrawal by subject | 4 | 0 |
| Withdrew: Subsequent infection | 2 | 0 |
Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI). 0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic
| Percent of resistant isolates | Infected Patients | Healthy Subjects |
|---|---|---|
| Day 0 | 0 | 0 |
| Day 42 | 0 | 0 |
Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI). 0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic
| Percent of resistant isolates | Infected Patients | Healthy Subjects |
|---|---|---|
| Day 0 | 8.3 | 0 |
| Day 42 | 0 | 0 |
Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI). 0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic
| Percent of resistant isolates | Infected Patients | Healthy Subjects |
|---|---|---|
| Day 0 | 0 | 0 |
| Day 42 | 0 | 0 |
Collected over Day 0 to Day 42. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infected Patients | — | 0/105 (0%) | 6/105 (5.7%) |
| Healthy Subjects | — | 0/57 (0%) | 0/57 (0%) |
| Event | Infected Patients | Healthy Subjects |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 6/105 | 0/57 |
| Age, Categorical(Participants) | Infected Patients | Healthy Subjects | Total |
|---|---|---|---|
| <=18 years | 105 | 57 | 162 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Infected Patients | Healthy Subjects | Total |
|---|---|---|---|
| Female | 48 | 28 | 76 |
| Male | 57 | 29 | 86 |
The record gives a start of Jun 2006, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin